GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Liabilities-to-Assets

NKGen Biotech (NKGen Biotech) Liabilities-to-Assets : 4.37 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. NKGen Biotech's Total Liabilities for the quarter that ended in Mar. 2024 was $71.37 Mil. NKGen Biotech's Total Assets for the quarter that ended in Mar. 2024 was $16.32 Mil. Therefore, NKGen Biotech's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 4.37.


NKGen Biotech Liabilities-to-Assets Historical Data

The historical data trend for NKGen Biotech's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Liabilities-to-Assets Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Liabilities-to-Assets
3.11 0.90 4.56

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial 0.90 - 2.61 4.56 4.37

Competitive Comparison of NKGen Biotech's Liabilities-to-Assets

For the Biotechnology subindustry, NKGen Biotech's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Liabilities-to-Assets falls into.



NKGen Biotech Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

NKGen Biotech's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=75.174/16.481
=4.56

NKGen Biotech's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=71.371/16.316
=4.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech  (NAS:NKGN) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


NKGen Biotech Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.